Brief: Helix BioPharma Corp Submits L-DOS47 IND Application With U.S. FDA For Pancreatic Cancer
09/07/2019 12:37
July 9 (Reuters) - Helix Biopharma Corp HBP.TO :
* HELIX BIOPHARMA CORP. SUBMITS L-DOS47 IND APPLICATION WITH
U.S.
FDA FOR PANCREATIC CANCER
* HELIX BIOPHARMA - SUBMISSION OF IND WITH U.S. FDA FOR
APPROVAL
TO INITIATE PHASE I/II CLINICAL STUDY PROTOCOL WITH L-DOS47 WITH
DOXORUBICIN
Source text for Eikon: ID:nGNX4wgTnT
Further company coverage: HBP.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020